07.20.21

Allergan to Present New Data from its Eye Care Portfolio at the 2021 ASCRS

Source: Allergan

Allergan announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) annual meeting being held July 23-27 in Las Vegas. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an investigational presbyopia treatment, and updated analyses on Durysta (bimatoprost intracameral implant), the first and only FDA-approved dissolvable implant to reduce eye pressure in people with open angle glaucoma or high eye pressure.       

“As a company, we remain committed to advancing care for difficult-to-treat eye conditions and diseases, such as presbyopia and glaucoma, that have a profound impact on daily life for millions of people,” Michael R. Robinson, MD, vice president, global therapeutic area head, eye care, AbbVie, said in a company news release. “Data presented at the 2021 ASCRS Annual Meeting will help us understand the potential for AGN-190584 to be a first-of-its-kind treatment option for those living with presbyopia, as well as augment our knowledge of DURYSTA, which has changed how physicians can care for patients with glaucoma.”

Researchers will present new data evaluating the efficacy, safety and tolerability of investigational AGN-190584 for the treatment of presbyopia, inclusive of full data results from the phase 3 GEMINI 1 study. GEMINI 1 data, in combination with data from the GEMINI 2 study, formed the basis of the AGN-190584 new drug application (NDA) currently under review with the FDA, which the agency is expected to act on by the end of 2021. 

Updated analyses from the phase 3 ARTEMIS studies assessing the efficacy and duration of Durysta will also be presented. Durysta was approved by the FDA in March 2020 to reduce IOP in patients with open angle glaucoma (OAG) or high eye pressure (ocular hypertension, or OHT). Allergan has continued to collect data to further understand how Durysta can best be used to benefit patients living with glaucoma.

Details about Allergan’s presentations are as follows:

 

 

Abstract

Linked to ASCRS program

 

Presentation Details

All Times PDT

 

Glaucoma

Duration of IOP Lowering with Bimatoprost Implant and Profile of the IOP-Lowering Response before Rescue in the Phase 3 Artemis Studies

Session: Minimally Invasive Glaucoma Surgery (MIGS) III

Sunday, July 25

2:05 – 2:10 p.m.

Room: MBCR – Level 2, Lagoon F

Bimatoprost Implant for IOP Lowering: Responder Rates Overall and in Subgroups By Previous Medication Count in the Phase 3 Artemis Studies

Session: Minimally Invasive Glaucoma Surgery (MIGS) III

Sunday, July 25

2:10 – 2:15 p.m.

Room: MBCR – Level 2, Lagoon F

Efficacy of Intracameral Bimatoprost Implant in Patients Stratified By Baseline IOP (≤25 or >25 mmHg) in the Phase 3 Artemis Studies

Session: Minimally Invasive Glaucoma Surgery (MIGS) III

Sunday, July 25

2:20 – 2:25 p.m.

Room: MBCR – Level 2, Lagoon F

 

Presbyopia

Gemini 1 Phase 3: AGN-190584 Improves Intermediate Vision in Participants with Presbyopia

Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies

Sunday, July 25

8:00 – 8:05 a.m.

Room: MBCR – Level 2, Lagoon F

Evaluating Vision-Related Reading Ability with a De Novo PRO Instrument in a Phase 3 Study of AGN-190584 (Pilocarpine 1.25%) for Presbyopia

Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies

Sunday, July 25

8:05 – 8:10 a.m.

Room: MBCR – Level 2, Lagoon F

Assessing Presbyopia Impacts and Coping Behaviors with De Novo PRO Instruments in a Phase 3 Study of AGN-190584 (Pilocarpine 1.25%)

Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies

Sunday, July 25

8:10 – 8:15 a.m.

Room: MBCR – Level 2, Lagoon F

Gemini 1 Phase 3: AGN-190584 Provides Rapid Improvement of Distance Corrected Near Vision That Is Maintained in Participants with Presbyopia

Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies

Sunday, July 25

8:15 – 8:20 a.m.

Room: MBCR – Level 2, Lagoon F

Gemini 1 Phase 3: Safety and Efficacy of AGN-190584 in Participants with Presbyopia

Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies

Sunday, July 25

8:25 – 8:30 a.m.

Room: MBCR – Level 2, Lagoon F

 

*ASCRS Disclaimer: All educational content of the ASCRS ASOA Annual Meeting is planned by its program committee, and ASCRS ASOA does not endorse, promote, approve, or recommend the use of any products, devices, or services.

 

Related Content